AtriCure Completes Acquisition of SentreHEART
August 13 2019 - 2:16PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced that it has completed its previously
announced acquisition of SentreHEART, Inc., a privately held
developer of percutaneous left atrial appendage management
solutions.
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA)
Exclusion System products are the most widely sold LAA management
devices worldwide. For more information, visit AtriCure.com or
follow us on Twitter @AtriCure.
About SentreHEART, Inc.
SentreHEART is a privately-owned medical device company based in
Redwood City, California. Founded in 2005, SentreHEART has
developed innovative technology for remote delivery of suture for
closure of anatomic structures including the LAA. The company is
committed to clinical evidence development and is currently
sponsoring the FDA-approved prospective, multi-center, randomized
controlled trial known as the aMAZE Trial. Information about the
aMAZE Trial can be found at: https://amazetrial.com/en/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190813005650/en/
Andy Wade AtriCure, Inc. Senior Vice President and Chief
Financial Officer (513) 755-4564 awade@AtriCure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2024 to May 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From May 2023 to May 2024